Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCRT vs Standard Maintenance in Oligometastatic NSCLC
NCT05278052Phase 3Recruiting
- Sponsor
- Tata Memorial Hospital
- Start
- Apr 2020
- Primary completion
- Apr 2026
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Tata Memorial Hospital. Primary endpoint: Overall Survival at 2 years. Started Apr 2020; status: recruiting.
Beyond the preview
Go deeper on NCT05278052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05278052.